Comment on BioNTech CEO applies Covid-19 vaccine's mRNA tech to multiple sclerosisparentComments−usehackernews5yI state that CRISPR benefits researchers. However, that is still a niche benefit relative to the long term societal benefits we anticipate from CRISPR.
Comments
I state that CRISPR benefits researchers. However, that is still a niche benefit relative to the long term societal benefits we anticipate from CRISPR.